Literature DB >> 8424578

Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication.

J G Regensteiner1, M E Hargarten, R B Rutherford, W R Hiatt.   

Abstract

Many patients with peripheral arterial disease (PAD) undergo peripheral bypass surgery to relieve the symptom of intermittent claudication. However, measurement of graft patency alone, assessed by change in ankle blood pressure, may not adequately reflect the improvement in functional status following the operation. Fourteen patients with moderately severe intermittent claudication were evaluated before and after bypass surgery to asses changes in hemodynamics (by resting ankle-brachial indices-ABIs), exercise performance (by a graded treadmill protocol), and community-based walking ability (by a questionnaire that characterizes self-reported walking speed and distance). Six weeks after surgery, resting ABIs improved in surgical patients (from 0.56 +/- 0.09 to 0.93 +/- 0.16, P < 0.05). Peak treadmill walking time improved from 6.2 +/- 5.9 to 11.8 +/- 7.1 min (90%), peak oxygen consumption from 15.5 +/- 6.5 to 19.1 +/- 8.5 mL/kg/min (23%), and pain-free walking time from 1.5 +/- 0.4 to 6.0 5.5 min (290%). Questionnaire scores for walking distance improved by 203% and for walking speed by 130% (all P < 0.05). After twelve weeks, improvements other than pain-free walking time were maintained. Changes in peak treadmill performance or questionnaire scores were not correlated with the initial ABI, changes in ABI six or twelve weeks after surgery, or the type or extent of bypass surgery. The results demonstrate that surgical treatment of PAD, indicated for the relief of intermittent claudication, improves exercise performance and self-reported community-based walking ability. The change in functional status of the patient is an important outcome of surgery that cannot be predicted from routine noninvasive testing alone and should be measured directly.

Entities:  

Mesh:

Year:  1993        PMID: 8424578     DOI: 10.1177/000331979304400101

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  27 in total

1.  Poorer clock draw test scores are associated with greater functional impairment in peripheral artery disease: the Walking and Leg Circulation Study II.

Authors:  Laura J Zimmermann; Luigi Ferrucci; Jack M Guralnik; Michael H Criqui; Mary M McDermott
Journal:  Vasc Med       Date:  2011-06       Impact factor: 3.239

2.  Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease.

Authors:  Jennifer L Robbins; W Schuyler Jones; Brian D Duscha; Jason D Allen; William E Kraus; Judith G Regensteiner; William R Hiatt; Brian H Annex
Journal:  J Appl Physiol (1985)       Date:  2011-04-21

3.  Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication.

Authors:  Emile R Mohler; John L Gainer; Kim Whitten; Luis H Eraso; Porama Koy Thanaporn; Timothy Bauer
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

4.  Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.

Authors:  Kristen A Baltgalvis; Kathy White; Wei Li; Mark D Claypool; Wayne Lang; Raniel Alcantara; Baljit K Singh; Annabelle M Friera; John McLaughlin; Derek Hansen; Kelly McCaughey; Henry Nguyen; Ira J Smith; Guillermo Godinez; Simon J Shaw; Dane Goff; Rajinder Singh; Vadim Markovtsov; Tian-Qiang Sun; Yonchu Jenkins; Gerald Uy; Yingwu Li; Alison Pan; Tarikere Gururaja; David Lau; Gary Park; Yasumichi Hitoshi; Donald G Payan; Todd M Kinsella
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-02-21       Impact factor: 4.733

Review 5.  Nitrite and nitric oxide metabolism in peripheral artery disease.

Authors:  Jason D Allen; Tony Giordano; Christopher G Kevil
Journal:  Nitric Oxide       Date:  2012-03-14       Impact factor: 4.427

6.  Inorganic nitrate supplementation enhances functional capacity and lower-limb microvascular reactivity in patients with peripheral artery disease.

Authors:  Joshua M Bock; David P Treichler; Samuel L Norton; Kenichi Ueda; William E Hughes; Darren P Casey
Journal:  Nitric Oxide       Date:  2018-08-15       Impact factor: 4.427

7.  A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.

Authors:  Reena L Pande; William R Hiatt; Peter Zhang; Norbert Hittel; Mark A Creager
Journal:  Vasc Med       Date:  2010-04-12       Impact factor: 3.239

Review 8.  Disruption of mitochondrial quality control in peripheral artery disease: New therapeutic opportunities.

Authors:  Cintia B Ueta; Katia S Gomes; Márcio A Ribeiro; Daria Mochly-Rosen; Julio C B Ferreira
Journal:  Pharmacol Res       Date:  2016-11-19       Impact factor: 7.658

9.  Leg symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease.

Authors:  M M McDermott; S Mehta; K Liu; J M Guralnik; G J Martin; M H Criqui; P Greenland
Journal:  J Gen Intern Med       Date:  1999-03       Impact factor: 5.128

Review 10.  Functional impairment in peripheral artery disease and how to improve it in 2013.

Authors:  Mary McGrae McDermott
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.